Trial Profile
A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects with Ankylosing Spondylitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Bimekizumab (Primary)
- Indications Ankylosing spondylitis
- Focus Adverse reactions
- Acronyms BE AGILE 2
- Sponsors UCB; UCB Biopharma
- 15 Nov 2023 5-yr results of Bimekizumab in BE AGILE and its OLE, presented at the ACR Convergence 2023
- 15 Nov 2023 Results of pooled analysis of studies (BE MOBILE 1, BE MOBILE 2, BE MOVING,BE MOBILE 1,BE MOBILE 2,BE AGILE, BE AGILE 2, assessing incidence of uveitis following inhibition of IL-7A in addition to IL-7F with bimekizumab in patients with Axial Spondyloarthritis were presented at the ACR Convergence 2023.
- 03 Jun 2023 Results of pooled analysis from NCT03928704, NCT03928743, NCT04436640, NCT02963506 and NCT03355573; presented at the 24th Annual Congress of the European League Against Rheumatism